Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — Bernstein's 38th Annual Strategic Decisions Conference 2022
15 slides from Edwards Lifesciences's conference presentation, Jun 2, 2022
Slide 1: Edwards Lifesciences
Edwards Lifesciences Bernstein’s 38th Annual Strategic Decisions Conference June 2, 2022
Slide 2: Cautionary Statement
Cautionary Statement Presentations and comments made today by management of Edwards Lifesciences Corporation (the “Company”) will include forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, a
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial measures. The Company uses the term "adjusted sales" or “underlying growth rate” when referring to non-GAAP sales information, which excludes foreign exchange rate fluctuations, the conversion to a consignm
Slide 4: Our Credo
Our Credo Through our actions, we will become trusted partners with customers, colleagues, and patients– creating a community unified in its mission to improve the quality of life around the world. Our results will benefit customers, patients, employees and shareholders. We will celebrate our succes
Slide 5: Our Aspirations
Our Aspirations Edwards is a global leader dedicated to… Transforming patient lives Delivering exceptional with breakthrough shareholder value medical technologies Excelling as a trusted partner Passionate engagement that through distinguished quality and strengthens our communities integrity Foster
Slide 6: Edwards Lifesciences at a Glance
Edwards Lifesciences at a Glance 600K+ 16,000+ Global Employees Patients Treated with Transcatheter Therapies ~2,000 80%+ 7 Engineers Charitable employee 50% + Manufacturing Facilities Around the engagement Millennials and Generation Z World Investment in R&D 95%+ 17% Sales from Products with #1 Glo
Slide 7: Patient-Focused Innovation Strategy
Patient-Focused Innovation Strategy Innovation Leadership Focus Pioneer breakthrough Lead groundbreaking Singular focus on the large technologies with standards of care through unmet needs of structural compelling evidence trusted relationships heart and critically ill patients Create Meaningful Val
Slide 8: Edwards' patient-focused innovation strategy has produced sustained underlying sales growth
Edwards’ patient-focused innovation strategy has produced sustained underlying sales growth Focused on Track record of Long-term opportunities where triple wins: investments have patient demand is Improved outcomes yielded high-value, very large Enhanced quality of life organic growth Cost eff
Slide 9: Leader in $5B Global Transcatheter Aortic Valve Replacement Market
Leader in $5B Global Transcatheter Aortic Valve Replacement Market Estimated global Primary global growth drivers: greater awareness, advances in new technologies, as well as indication and geographic TAVR opportunity expansion $10B by 2028 Globally, diagnosis and treatment rates of AS remain low pr
Slide 10: TMTT focused on leading and transforming treatment for patients with mitral and tricuspid valve disease
TMTT focused on leading and transforming treatment for patients with mitral and tricuspid valve disease Three key value drivers: a portfolio of differentiated therapies, Estimated global positive results from pivotal clinical trials and excellent real- TMTT opportunity world clinical outcomes $5B by
Slide 11: Surgical Structural Heart is transforming patients' lives by solving critical unmet needs in cardiac surgery
Surgical Structural Heart is transforming patients’ lives by solving critical unmet needs in cardiac surgery Estimated global The surgical structural heart market will continue to grow surgical structural heart mid-single digits to $2B by 2028 market opportunity We closely partner with surgeons to u
Slide 12: Critical Care improving the quality of care for patients
Critical Care improving the quality of care for patients Estimated global Continuing to shift product mix towards Smart Recovery, hemodynamic monitoring which has highest growth potential within Critical Care market opportunity ~$2B by 2028 Focusing on three key building blocks to advance Smart Reco
Slide 13: Nearly $20B Global Market Opportunity by 2028
Global Market Opportunity by 2028 Currently around $10 billion TAVR $10B TMTT $5B Surgical $2B Nearly Critical Care ~$2B $20B We are just getting started June 2022 13
Slide 14: Edwards is poised for long-term value creation
Edwards is poised for long-term value creation Large Populations Patient-Focused Culture Sustainable of patients with unmet needs motivates and guides our global team organic long-term sales growth Credibility and Trust Innovative R&D with clinicians, regulators, produces breakthrough therapies payo
Slide 15: Helping Patients is Our Life's Work
| Ee ee Edwards Helping Patients is Our Life’s Work, and, now fife?
Edwards Lifesciences — Bernstein's 38th Annual Strategic Decisions Conference 2022 on 6ix